Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency
Open accessAbstract
Background mRNA vaccines hold great potential as therapeutic techniques against viral infections due to their efficacy, safety, and large-scale production. mRNA vaccines offer flexibility in development as any protein can be produced from mRNA without altering the production or application process.Objective This review highlights the iterative optimization of mRNA vaccine structural elements that impact the type, specificity, and intensity of immune responses leading to higher translational potency and intracellular stability.Results Modifying the mRNA structural elements particularly the 5' cap, 5'-and 3'-untranslated regions (UTRs), the coding region, and polyadenylation tail help reduce the excessive mRNA immunogenicity and consistently improve its intracellular stability and translational efficiency.Conclusion Further studies regarding mRNA-structural elements and their optimization are needed to create new opportunities for engineering mRNA vaccines.
AI snapshot
Written from the paper’s full text.
TL;DR
This narrative review summarizes how iterative optimization of mRNA vaccine structural elements—the 5′ cap, 5′- and 3′-UTRs, the coding region (ORF), and the poly(A) tail—can reduce excessive mRNA immunogenicity while improving intracellular stability and translational efficiency. It frames these modifications as the basis for the rapid development and >90% efficacy of the BNT162b2 and mRNA-1273 COVID-19 vaccines.
Key findings
- Modifying mRNA structural elements (5′ cap, 5′- and 3′-UTRs, coding region, poly(A) tail) reduces excessive mRNA immunogenicity and consistently improves intracellular stability and translational efficiency.
- Higher GC content translates 100-fold higher than a low GC sequence, though high GC can cause problems for mRNA secondary structure; codon optimization affects translation efficiency, mRNA abundance, and protein folding.
- Nucleoside modification lowers immunogenicity while increasing translation: Kormann et al. reported that 2 weeks after injection of mRNA containing 25% thio-uridine and 25% 5-methylcytidine, Epo levels were five times greater than in untreated animals, whereas unmodified mRNA showed no significant alterations and elicited a considerable immunological response.
- ARCA-capped mRNA showed translation efficiency twice that of mRNA capped by a conventional cap analog in rabbit reticulocyte lysate, and had a longer half-life in cultured cells; poly(A) tails of approximately 100 nt are described as ideal for mRNA therapeutics (mammalian cell mRNAs carry ~250 nt tails).
- BNT162b2 and mRNA-1273 both use N1-methylpseudouridine (1mΨ) modification and dsRNA fragment removal; both encode spike proteins with K986P and V987P substitutions, and both have efficacy above 90% (~95%).
Methods
- Design: narrative review of mRNA vaccine structural element design and modification, drawing on cited primary literature rather than presenting new experimental data.
- Scope: covers the ORF, 5′- and 3′-UTRs, 5′ capping, the poly(A) tail, immunogenicity elimination, advantages of mRNA vaccines, and the COVID-19 mRNA vaccines BNT162b2 and mRNA-1273.
- Main analysis: qualitative synthesis organized around each structural element, with a summary table (Table 1) mapping each element's modification to its effect (e.g., UTR length/structure → modulate translation efficiency; cap structure → increase protein synthesis and stability; codon optimization → enhance protein expression; poly(A) tail elongation → increase stability and translational efficiency).
Limitations
- Stated in the paper: the most difficult task needing attention is striking a balance between translation efficiency and immune response to provide appropriate and safe immunogenicity; further studies on mRNA structural elements and their optimization are needed.
- Stated in the paper: despite the advantages of mRNA vaccines, many risks remain—long-term effects of mRNA vaccines are unknown, and mRNA is unstable and must be stored at high temperature, making packaging and distribution difficult (the paper also notes cold-chain storage/transport as a major technical and financial challenge).
- Evident from the text: as a narrative review, it presents no primary data, systematic search strategy, or quantitative synthesis; several cited findings are attributed to other studies, and Moderna's structural elements are described as undisclosed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
30 of 80 cited sources checked · 17 supported · 1 flagged · accuracy not yet measured
- Premisecitation
A higher GC sequence translates 100-fold higher than a low GC sequence.
“Although high GC-content may cause problems for mRNA secondary structure, the higher GC sequence translates 100-fold higher than a low GC sequence (Kudla et al. 2006).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Kudla et al. 2006 source
The Results (page unavailable) attribute higher protein output from GC-rich GFP to higher mRNA levels, not a higher translation rate. The Discussion likewise says codon optimization increased GFP mRNA levels rather than its translation rate. The claimed 100-fold increase in translation is therefore contrary to the paper's finding. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
- Premisecitation
α- and β-globin 3′ UTRs contain sequence features that enhance the translation and stability of mRNA.
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
Quote in the paperSubstantial claim1 of 2 sources checked - Interpretationcitation
Modified nucleosides can be used to create mRNA vaccines with significantly improved translation efficiency.
“The modified nucleosides escape the type interferons (IFNs) induced antiviral pathways and are targeted to break and block invading mRNA; therefore they can be used to create mRNA vaccines with significantly improved translation efficiency (Verbeke et al. 2019).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Verbeke et al. 2019 source
- Premisecitation
The translation elongation rate is controlled by the accessibility of cognate tRNA species and codon usage modification.
“The translation elongation rate is controlled by the accessibility of cognate tRNA species and the codon usage modification to prevent the match rare tRNA sequence of species and integrate sequences that match more common tRNA species (Hanson and Coller 2018).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Hanson and Coller 2018 source
- Premisecitation
5′-capping promotes pre-mRNA splicing.
“Screening mRNA against exonuclease activity, promoting pre-mRNA splicing, and functioning as binding site of eIF4F heterodimeric translation initiation complex are all important functions of 5′-capping (Izaurralde et al. 1994; Gallie 1991).”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites Izaurralde et al. 1994 source
- cites Gallie 1991 source
The paper’s opening discussion and Discussion section address the cap’s roles in translation and mRNA stability, not pre-mRNA splicing. Searches for splicing and for cap-dependent removal of introns found no passage stating that capping promotes splicing; a splicing study appears only in the References. (LLM, conf=0.75)
Experimental — accuracy not yet measured
- Premisecitation
The 5′-cap structure is a key factor in the host's ability to differentiate between self and non-self mRNA molecules.
“The 5′-cap structure is a key factor in the host's ability to differentiate between self and non-self mRNA molecules (Devarkar et al. 2016).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Devarkar et al. 2016 source
- Premisecitation
The structural characteristics of mRNA such as the CAP, poly(A) tail, and UTRs directly impact mRNA stability and translation efficiency.
“The structural characteristics of mRNA such as the CAP, poly(A) tail, and untranslated regions (UTRs) directly impact mRNA stability and translation efficiency (Orlandini von Niessen et al. 2019; Holtkamp et al. 2006).”
Quote in the paperSubstantial claim1 of 2 sources checked - Premisecitation
Shorter 5′UTRs are better for mRNA translation.
“(iii) Shorter 5′UTRs may be used, as past research has indicated that this type of 5′UTR is better for mRNA translation (Leppek et al. 2018).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Leppek et al. 2018 source
The section ‘5′ UTRs as platforms for RNA structure’ describes variation in UTR length but does not compare translation efficiency by length. ‘5′ UTR structures in ribosome scanning’ notes that some exceptionally short UTRs permit scanning-free initiation; it does not say shorter UTRs are generally better for translation. Searches for short UTRs and translational efficiency found no such comparison in our copy. (LLM, conf=0.70)
Experimental — accuracy not yet measured
- Premisecitation
The 3′ UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA.
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
Quote in the paperNot a substantial claim1 of 2 sources checked - Premisecitation
The steady effect of human β-globin 3′ UTR sequences is enhanced when two human β-globin 3′ UTRs are placed in a head-to-tail orientation.
“The steady effect of human β-globin 3ʹ-UTR sequences is enhanced when two human β-globin 3ʹ-UTRs are placed in a head-to-tail orientation (Holtkamp et al. 2006).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Holtkamp et al. 2006 source
- Premisecitation
The length of the poly(A) tail is proportional to translation efficiency.
“The poly(A) tail steadies mRNA and boosts protein translation, and the length of the poly(A) tail is proportional to translation efficiency.”
Quote in the paperSubstantial claim2 of 2 sources checked- cites Park et al. 2016 source
In “Translational Regulation and Poly(A) Tail Control during the Somatic Cell Cycle” (Figure 3B), the paper reports a relationship between tail length and translation efficiency only for short tails, up to about 20 nt. It says lengthening beyond that does not further influence translation, so the unqualified claim of proportionality overstates the finding. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites Jalkanen et al. 2014 source
The Introduction says poly(A) tails can enhance translation efficiency. But “Does size matter?” reports a relationship between tail length and translation in early development and certain other contexts, while noting that a global analysis found no significant correlation beyond embryonic stages. The source therefore does not support an unqualified, proportional relationship. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Premisecitation
mRNA secondary structure design can be modified to improve mRNA stability against endonuclease cleavage and chemical degradation.
“Furthermore, mRNA secondary structure design can be modified to improve mRNA stability against endonuclease cleavage and chemical degradation (Wayment-Steele et al. 2021).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Wayment-Steele et al. 2021 source
- Premisecitation
Codon modification is critical for mRNA stability.
“Furthermore, the rate of codon-dependent translation elongation has been a primary factor of mRNA stability, codon modification is critical for mRNA stability (Presnyak et al. 2015).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Presnyak et al. 2015 source
- Premisecitation
The poly(A) tail is a critical factor in determining the longevity of mRNA molecules.
“It is a critical factor in determining the longevity of mRNA molecules (Park et al. 2016; Jalkanen et al. 2014).”
Quote in the paperSubstantial claim2 of 2 sources checked - Premisecitation
Increasing the G-C fraction of mRNA improves mRNA stability.
“Furthermore, increasing the G-C fraction of mRNA improves mRNA stability (Homma et al. 2016).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Homma et al. 2016 source
The Introduction and Discussion address codon usage, translation speed, and translational accuracy, not mRNA stability. Searches for increased G-C fraction, GC content, and mRNA stability found no passage in our copy supporting the claimed effect. (LLM, conf=0.76)
Experimental — accuracy not yet measured
- Premisecitation
The immunogenicity of mRNA is the most challenging obstacle it faces.
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Sahin et al. 2014 source
The “Immune-stimulatory activity of IVT mRNA” section calls innate immune activation a major disadvantage for protein-replacement therapies, but an added benefit for vaccination. It does not identify immunogenicity as the most challenging obstacle for mRNA generally; the “Progress in improving mRNA delivery” section also describes substantial delivery challenges. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Premisecitation
mRNA vaccines must be stored and carried at extremely low temperatures compared to protein-based vaccinations that can be stored and transported at lower temperatures.
“mRNA vaccines must be stored and carried at extremely low temperatures as compared to protein-based vaccinations that can be stored and transported at lower temperatures (Crommelin et al. 2020).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Crommelin et al. 2020 source
The Introduction describes mRNA vaccine candidates kept at −80 °C and the difficulty of transporting them under those conditions. The storage-conditions table lists frozen storage for three COVID-19 mRNA candidates, but also limited periods at 2–8 °C; the claim's unqualified “must” is too broad. Our copy does not provide the asserted comparison with protein-based vaccines. (LLM, conf=0.87)
Experimental — accuracy not yet measured
- Premisecitation
Substituting rare codons with identical frequent codons boosts yield.
“Substituting rare codons with identical frequent codons boosts yield as reusing same tRNA speeds up translation due to amino-acylation of tRNAs near ribosomes (Cannarozzi et al. 2010).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Cannarozzi et al. 2010 source
Checked before — its earlier verdict is held back until a new check runs.
- Premisenone given
The 5′ cap shields RNA from exonuclease cleavage.
“The 5′ cap regulates pre-mRNA splicing and nuclear export, works as a protective structure that shields RNA from exonuclease cleavage, and initiates mRNA translation.”
Quote in the paperSubstantial claim - Interpretationnone given
Modifying the mRNA structural elements, particularly the 5′ cap, 5′ and 3′ UTRs, the coding region, and polyadenylation tail, reduces excessive mRNA immunogenicity.
“Modifying the mRNA structural elements particularly the 5′ cap, 5′-and 3′-untranslated regions (UTRs), the coding region, and polyadenylation tail help reduce the excessive mRNA immunogenicity and consistently improve its intracellular stability and translational efficiency.”
Quote in the paperSubstantial claim - Premisecitation
ARCA-capped mRNA has twice the translation efficiency of mRNA capped by a conventional cap analog in rabbit reticulocyte lysate.
“When ARCA-capped mRNA was compared to mRNA capped by a conventional cap analog, translation efficiency was twice more than in rabbit reticulocyte lysate (Stepinski et al. 2001).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Stepinski et al. 2001
- Premisecitation
Deleting the poly(A) region from mRNA results in mRNA being unstable compared to the intact gene.
“Deleting the poly(A) region from mRNA results in mRNA being unstable compared to the intact gene (Whitelaw et al. 1986).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Whitelaw et al. 1986 source
Checked before — its earlier verdict is held back until a new check runs.
- Premisecitation
Inserting AU-rich regions into 3′-UTRs ensures fast mRNA breakdown and a short duration of protein expression.
“This effect can be achieved by inserting AU-rich regions into 3′-UTRs ensuring fast mRNA breakdown and a short duration of protein expression (Chen and Shyu 1995).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Chen and Shyu 1995 source
- Premisereasoning
The 5′ cap initiates mRNA translation.
“The 5′ cap regulates pre-mRNA splicing and nuclear export, works as a protective structure that shields RNA from exonuclease cleavage, and initiates mRNA translation.”
Quote in the paperSubstantial claim - Premisecitation
The length of the poly(A) tail is linked to translation efficiency.
“Several studies have linked the length of the poly(A) tail to translation efficiency (Conry et al. 1995).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Conry et al. 1995
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationnone given
Avoiding highly stable secondary structures in the 5′ UTR prevents ribosome recruitment and codon recognition.
“(ii) Ribosome recruitment and codon recognition can be prevented by avoiding the existence of highly stable secondary structures”
Quote in the paperSubstantial claim - Interpretationreasoning
Modifying the mRNA structural elements, particularly the 5′ cap, 5′ and 3′ UTRs, the coding region, and polyadenylation tail, improves intracellular stability and translational efficiency.
“Modifying the mRNA structural elements particularly the 5′ cap, 5′-and 3′-untranslated regions (UTRs), the coding region, and polyadenylation tail help reduce the excessive mRNA immunogenicity and consistently improve its intracellular stability and translational efficiency.”
- Also stated in: § Introduction · plain
“This review discussed the iterative optimization and significant modifications of the mRNA structure particularly the 5′ cap, 5′ and 3′UTRs, the coding region, and the poly(A) tail which improve the stability, translation capacity and increase the efficacy of mRNA vaccines to trigger the immune response.”
Quote in the paperSubstantial claim - Also stated in: § Introduction · plain
- Premisenone given
For mRNA stability and efficient translation, mRNA undergo post-transcriptional changes such as 5′-capping and poly(A).
“For mRNA stability and efficient translation, mRNA undergo post-transcriptional changes such as 5′-capping and poly(A).”
Quote in the paperSubstantial claim - Premisenone given
By interacting with RNA-binding proteins, UTRs can influence the rate of mRNA degradation and translation efficiency.
“By interacting with RNA-binding proteins, UTRs can also influence the rate of mRNA degradation and translation efficiency.”
Quote in the paperSubstantial claim - Premisecitation
Using enzymes to cap the 5′ terminus of mRNA is more efficient than using cap analogs such as 7-methylguanosine.
“Using enzymes to cap the 5′ terminus of mRNA is more efficient than using cap analogs such as 7-methylguanosine (Jani and Fuchs 2012; Urbina and Morales-Pison 1633).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites Jani and Fuchs 2012
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites Urbina and Morales-Pison 1633
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
The most prevalent ARCA enables only the insertion of a nucleotide at the non-methylated guanosine after 3′-O-methylation of base-methylated guanosine.
“The most prevalent ARCA enables only the insertion of a nucleotide at the non-methylated guanosine after 3′-O-methylation of base-methylated guanosine.”
Quote in the paperNot a substantial claim - Premisecitation
The translational elongation rate and efficiency are affected by neighboring nucleotides and codons.
“The translational elongation rate and efficiency are also affected by the neighboring nucleotides and codons (Bossi and Ruth 1980).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Bossi and Ruth 1980 source
- Premisecitation
5′-capping screens mRNA against exonuclease activity.
“Screening mRNA against exonuclease activity, promoting pre-mRNA splicing, and functioning as binding site of eIF4F heterodimeric translation initiation complex are all important functions of 5′-capping (Izaurralde et al. 1994; Gallie 1991).”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationnone given
mRNA sequence codon optimization can significantly impact the protein production rate and ribosome bide time.
“mRNA sequence codon optimization can significantly impact the protein production rate and ribosome bide time.”
Quote in the paperSubstantial claim - Premisereasoning
A functional 5′ cap structure is required for robust mRNA translation.
“A functional 5′ cap structure is required for robust mRNA translation.”
Quote in the paperSubstantial claim - Premisenone given
The cap 0 structure of m7GpppN is necessary for effective mRNA translation.
“The cap 0 structure of m7GpppN is necessary for effective mRNA translation.”
Quote in the paperSubstantial claim - Premisecitation
Injection of nucleoside-modified mRNA containing 25% thio-uridine and 25% 5-methylcytidine resulted in Epo levels five times greater than untreated animals 2 weeks after injection.
“Kormann et al., demonstrated that 2 weeks following injection of nucleoside-modified mRNA containing 25% thio-uridine and 25% 5-methylcytidine resulted in Epo levels five times greater than that in untreated animals.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Kormann et al. 2011 source
- Interpretationreasoning
The Cap and poly(A) tail at the 5′ and 3′ ends of mRNA are critical for stability of mRNA in the cytosol.
“The Cap and poly(A) tail located at the 5′- and 3′-ends of mRNA are critical for stability of mRNA in the cytosol.”
Quote in the paperSubstantial claim - Premisecitation
Substituting the mRNA sequence with rare codons and inserting modified nucleotides most likely alters mRNA structure, translational efficiency, and protein-folding machinery.
“The mRNA structure, translational efficiency, and protein-folding machinery are most likely to be altered by substituting the mRNA sequence with rare codons and inserting modified nucleotides (Zhong et al. 2017).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Zhong et al. 2017 source
- Premisecitation
The rate of codon-dependent translation elongation is a primary factor of mRNA stability.
“Furthermore, the rate of codon-dependent translation elongation has been a primary factor of mRNA stability, codon modification is critical for mRNA stability (Presnyak et al. 2015).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Presnyak et al. 2015 source
Not checked in the free run.
- Premisenone given
The employment of anti-reverse cap analogs results in a cap that is in the correct orientation (ARCAs).
“The employment of “anti-reverse” cap analogs results in a cap that is in the correct orientation Anti-Reverse Cap Analog (ARCAs).”
Quote in the paperSubstantial claim - Premisecitation
mRNA transcribed in vitro using ARCA has a longer half-life in cultivated cells.
“Furthermore, mRNA transcribed in vitro using ARCA has been found to have a longer half-life in cultivated cells (Grudzien et al. 2006).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Grudzien et al. 2006 source
Checked before — its earlier verdict is held back until a new check runs.
- Premisecitation
The 5′ and 3′ UTRs regulate mRNA stability.
“The 5′- and 3′- UTRs comprising of regulatory sequence elements are known to regulate the mRNA stability.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Tanguay and Gallie 1996 source
Checked before — its earlier verdict is held back until a new check runs.
- Interpretationreasoning
Avoiding start codons and non-canonical start codons in the 5′ UTR improves mRNA stability and translation accuracy by preventing disruption of ORF translation.
“The 5′ UTR sequence can be adjusted to improve mRNA stability and translation accuracy by (i) avoiding the presence of start codons and non-canonical start codons in the 5′ UTR which disrupts ORF translation”
Quote in the paperSubstantial claim - Premisenone given
Distinct areas of cellular and viral 5′ and 3′ UTRs improve mRNA stability and efficiency of translation.
“Furthermore, distinct areas of cellular and viral 5ʹ- and 3ʹ-UTRs improve mRNA stability and efficiency of translation.”
Quote in the paperSubstantial claim - Premisecitation
5′-capping functions as binding site of eIF4F heterodimeric translation initiation complex.
“Screening mRNA against exonuclease activity, promoting pre-mRNA splicing, and functioning as binding site of eIF4F heterodimeric translation initiation complex are all important functions of 5′-capping (Izaurralde et al. 1994; Gallie 1991).”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
mRNA needs 5′ and 3′ UTRs around the ORF to increase half-life, vaccine mRNA expression levels, and translation.
“mRNA also need 5′ and 3′ UTRs around the open reading frame (ORF) to increase half-life, vaccine mRNA expression levels, and translation (Conry et al. 1995).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Conry et al. 1995
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Codon composition influences translation efficiency.
“Codon composition is known to influence translation efficiency.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Kudla et al. 2006 source
Not checked in the free run.
- Interpretationreasoning
The 5′-UTR/3′-UTR, 5′ cap, poly(A) tail, rare codon and G:C content can be optimized to improve mRNA stability.
“The 5′-UTR/3′-UTR, 5′ cap, the poly(A) tail, a rare codon and G:C content can be optimized to improve mRNA stability.”
Quote in the paperSubstantial claim - Premisecitation
The poly(A) tail is important for mRNA stability and translation success.
“The poly(A) tail is important for mRNA stability and translation success (Kudla et al. 2006).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Kudla et al. 2006 source
Not checked in the free run.
- Interpretationreasoning
The intensity and specificity of immune responses are expected to be influenced by changes in mRNA structure, translational efficiency, and protein-folding machinery.
“The intensity and specificity of the immune responses are expected to be influenced by these changes.”
Quote in the paperSubstantial claim- Rests on an assumption: The intensity and specificity of the immune responses are influenced by changes in mRNA structure, translational efficiency, and protein-folding machinery.
- Premisenone given
Optimizing mRNA with a GC-rich sequence minimizes mRNA immunogenicity.
“Chemically altering nucleotides, adding poly(A) tails, and optimizing mRNA with a GC-rich sequence are efficient ways to minimize mRNA immunogenicity.”
Quote in the paperSubstantial claim - Premisereasoning
Adding poly(A) tails minimizes mRNA immunogenicity.
“Chemically altering nucleotides, adding poly(A) tails, and optimizing mRNA with a GC-rich sequence are efficient ways to minimize mRNA immunogenicity.”
Quote in the paperSubstantial claim - Premisecitation
With the advancement of lipid nanoparticle techniques, mRNA vaccine stability can be maintained under less rigorous settings.
“However, with the advancement of lipid nanoparticle techniques, mRNA vaccine stability can be maintained under less rigorous settings (Reichmuth et al. 2016).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Reichmuth et al. 2016 source
Not checked in the free run.
- Interpretationnone given
mRNA purification is required after IVT to eliminate immunogenicity.
“mRNA purification is also required after IVT to eliminate immunogenicity.”
Quote in the paperNot a substantial claim - Premisecitation
High GC concentration reduces the efficacy of protein expression.
“The reduced efficacy of protein expression produced by high GC concentration needs to be addressed (Wang et al. 2021).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Wang et al. 2021 source
Checked before — its earlier verdict is held back until a new check runs.
- Interpretationreasoning
Storing and transferring mRNA vaccines to and from warm countries is a major technical and financial challenge.
“Storing and transferring mRNA vaccines to and from warm countries is thus a major technical and financial challenge.”
Quote in the paperNot a substantial claim - Premisereasoning
Chemically altering nucleotides minimizes mRNA immunogenicity.
“Chemically altering nucleotides, adding poly(A) tails, and optimizing mRNA with a GC-rich sequence are efficient ways to minimize mRNA immunogenicity.”
Quote in the paperSubstantial claim - Interpretationreasoning
Using structurally modified mRNA may be better for eliciting a rapid antibody response, as highlighted by the COVID-19 mRNA vaccine.
“The COVID-19 mRNA vaccine highlight that using structurally modified mRNA allows for increased dose tolerance and may be better for eliciting a rapid antibody response.”
Quote in the paperNot a substantial claim - Interpretationnone given
Using structurally modified mRNA allows for increased dose tolerance, as highlighted by the COVID-19 mRNA vaccine.
“The COVID-19 mRNA vaccine highlight that using structurally modified mRNA allows for increased dose tolerance and may be better for eliciting a rapid antibody response.”
Quote in the paperNot a substantial claim - Premisecitation
5-methylcytidine (m5C) and pseudouridine (ψ) are the most preferred base-pair alterations because they lower immunogenicity while increasing translation efficiency.
“5-methylcytidine (m5C), and pseudouridine (ψ) are the most preferred base-pair alterations because they lower immunogenicity while increasing translation efficiency (Weng 2020).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Weng 2020 source
- Premisecitation
BNT162b2 and mRNA-1273 used a mixture of altered nucleotide 1mΨ modifications and dsRNA fragment eviction in the mRNA manufacturing procedure to significantly lower innate immune signaling in response to mRNA.
“BNT162b2 (BioNTech/Pfizer) and mRNA-1273 (Moderna) used a mixture of altered nucleotide 1mΨ modifications and dsRNA fragment eviction in the mRNA manufacturing procedure to significantly lower innate immune signaling in response to mRNA (Walsh et al. 2020; Jackson et al. 2020b).”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisenone given
Antigen translation occurs in the cytoplasm rather than the nucleus.
“Because antigen translation occurs in the cytoplasm rather than the nucleus; therefore mRNA vaccines have a greater biosafety than DNA vaccines as their antigens are translated into the cytoplasm rather than the nucleus, making it more difficult for the mRNA to integrate into the genome.”
Quote in the paperSubstantial claim - Premisereasoning
As soon as the sequence encoding the immunogen is available, RNA synthesis may begin on the same platform.
“As soon as the sequence encoding the immunogen is available, RNA synthesis may begin on the same platform.”
Quote in the paperNot a substantial claim - Premisecitation
The insertion of modified nucleotides into the poly(A) tail by recombinant poly(A) polymerase inhibits deadenylation by poly(A)-specific nucleases.
“The insertion of modified nucleotides into the poly(A) tail by recombinant poly(A) polymerase inhibits deadenylation by poly(A)-specific nucleases (Korner and Wahle 1997).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Korner and Wahle 1997 source
Checked before — its earlier verdict is held back until a new check runs.
- Interpretationcitation
Immunizing against the full S protein rather than just one of its structural units may lead to a better response that is not impacted by genetic drift.
“Therefore, immunizing against the full S protein rather than just one of its structural units may lead to a better response that is not impacted by genetic drift (Liu et al. 2020).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Liu et al. 2020 source
Not checked in the free run.
- May combine two claims. 30
- Classified as probably not a substantial claim. 28
- The quote only partly states this claim. 1
May combine two claims.
PremisecitationModified nucleosides escape type interferons (IFNs) induced antiviral pathways and are targeted to break and block invading mRNA.
“The modified nucleosides escape the type interferons (IFNs) induced antiviral pathways and are targeted to break and block invading mRNA; therefore they can be used to create mRNA vaccines with significantly improved translation efficiency (Verbeke et al. 2019).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Verbeke et al. 2019 source
May combine two claims.
PremisecitationThe poly(A) tail steadies mRNA and boosts protein translation.
“The poly(A) tail steadies mRNA and boosts protein translation, and the length of the poly(A) tail is proportional to translation efficiency.”
Quote in the paperSubstantial claim2 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationmRNA is created via a cell-free enzymatic transcription reaction that enables rapid and scalable production.
“mRNA is created via a cell-free enzymatic transcription reaction that enables rapid and scalable production, as illustrated by the current pandemic's rapid pursuit of RNA vaccines (Verbeke et al. 2021).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Verbeke et al. 2021 source
In “COVID-19 creates momentum for mRNA vaccines” (page unavailable), the paper discusses in vitro-transcribed (IVT) mRNA, and “Conclusions and perspectives” describes exceptionally rapid development and production of COVID-19 mRNA vaccines. It does not explicitly describe a cell-free enzymatic transcription reaction; the scalable production system it identifies is microfluidic mixing to formulate mRNA-loaded nanoparticles, not transcription itself. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Classified as probably not a substantial claim.
PremisecitationThe basic structure of mRNA is made up of a protein-encoding ORF, surrounded by 5′ and 3′ UTRs, a 7-methyl guanosine 5′ cap structure, and a 3′ poly(A) tail.
“The basic structure of mRNA, same as eukaryotic mRNA, is made up of (i) protein encoding ORF, surrounded by (ii) 5′ and 3′ UTRs, and (iii) a 7-methyl guanosine 5′ cap structure and (iv) a 3′poly(A) tail at the end sides (Verbeke et al. 2019; Schlake et al. 2012; Sahin et al. 2014) (Fig. 1).”
Quote in the paperSubstantial claim3 of 3 sources checkedMay combine two claims.
PremisecitationN1-methyl-pseudouridine (1mΨ) nucleotide substitution increases base pair stability, resulting in complex secondary structure and improved mRNA translation.
“N1-methyl-pseudouridine (1mΨ) nucleotide substitution has been found to increase base pair stability, resulting in complex secondary structure and improved mRNA translation (Mauger et al. 2019).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Mauger et al. 2019 source
The Discussion reports that m1Ψ stabilizes base pairing and mRNA secondary structure and generally increases protein output. But the Results section, “Codon Usage and mRNA Structure Synergize to Determine Ribosome Loading and mRNA Half-Life,” finds that protein output correlates poorly with translation rate and strongly with functional mRNA half-life. Thus the structural and protein-output parts are supported, but “improved mRNA translation” overstates the measured mechanism. (LLM, conf=0.86)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationBNT162b2 includes N1-methylpseudouridine, optimized codon, high GC sequence, removed dsRNA, and N1-methylpseudouridine modifications.
“The BNT162b2 includes N1-methylpseudouridine, optimized codon; high GC sequence, removed dsRNA, and N1-methylpseudouridine modifications (Polack et al. 2020).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Polack et al. 2020 source
The Abstract Methods identifies BNT162b2 as a nucleoside-modified RNA vaccine, supporting the general modification claim. Our copy does not specify N1-methylpseudouridine, codon optimization, high GC content, or removal of double-stranded RNA; searches for those terms found no supporting passage. Page numbers were not available in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationModerna used N1-methylpseudouridine, removed dsRNA, and undisclosed structural elements.
“Moderna on the other hand used N1-methylpseudouridine, removed dsRNA, and undisclosed structural elements (Baden et al. 2021) (Fig. 2A).”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites Baden et al. 2021 source
The Background (p. 1) describes mRNA-1273 as an mRNA vaccine encoding a stabilized spike protein, but does not specify its nucleoside modifications or manufacturing steps. Searches for N1-methylpseudouridine, dsRNA removal, and structural elements found no passage in our copy addressing those claims. (LLM, conf=0.73)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationExtraction of neutralizing antibodies from COVID-19 patient serum verified the S protein's high immunogenicity, and the receptor binding domain (RBD) and N-terminal domains were also equally immunogenic.
“The extraction of neutralizing antibodies from COVID-19 patient’s serum verified the S protein’s high immunogenicity, whereas the receptor binding domain (RBD) and N-terminal domains were also equally immunogenic (NTD).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Liu et al. 2020 source
The opening summary (p. 1) reports neutralizing antibodies from five COVID-19 patients and says the potent antibodies were about equally divided between RBD and NTD targets, indicating that both spike regions are immunogenic. But “Isolation and construction of mAbs” (p. 2) describes sorting spike-binding memory B cells from blood and producing monoclonal antibodies from their sequences, not extracting antibodies from patient serum. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe bulk of the mRNA vaccines reported till date have an m7GpppNm cap inserted at the 5′-end during IVT.
“The bulk of the mRNA vaccines reported till date have an m7GpppNm cap inserted at the 5′-end during IVT (Corbett et al. 2020).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Corbett et al. 2020 source
Not checked in the free run.
May combine two claims. The quote only partly states this claim.
PremisecitationMice administered HPLC-purified and m1ψ modified mRNA with lipid nanoparticle produced protective antibodies, assisting them in overcoming HIV-1 infection.
“The findings revealed that mice administered mRNA-LNP produced protective antibodies, assisting them in overcoming HIV-1 infection (Pardi et al. 2017).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Pardi et al. 2017 source
Not checked in the free run.
May combine two claims.
PremisecitationSome proteins require delayed translation for appropriate folding, which is guaranteed by uncommon codons.
“For appropriate folding, some proteins require delayed translation, which is guaranteed by uncommon codons (Kimchi-Sarfaty et al. 2007).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Kimchi-Sarfaty et al. 2007 source
Checked before — its earlier verdict is held back until a new check runs.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe basic concept underlying mRNA vaccines is to encode the antigen in mRNA and transfer the transcript to the host cell's cytoplasm via a non-viral delivery route, permitting antigen expression and stimulation of an antigen-specific immune response.
“The basic concept underlying mRNA vaccines is to encode the antigen in mRNA and transfer the transcript to the host cell’s cytoplasm via a non-viral delivery route, permitting antigen expression and stimulation of an antigen-specific immune response (Jackson et al. 2020).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Jackson et al. 2020
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
InterpretationcitationDestabilizing mRNA may be useful in some applications to reduce the time required for protein synthesis.
“Destabilizing mRNA may be useful in some applications to reduce the time required for protein synthesis.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationmRNA transcripts containing modified nucleosides are created with lower immunostimulatory activity and a better safety profile.
“mRNA transcripts containing modified nucleosides, also known as nucleoside-modified mRNAs, are created with lower immunostimulatory activity and a better safety profile.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Verbeke et al. 2019 source
Not checked in the free run.
May combine two claims.
Premisecitation5′-UTR regulatory elements and the length of the 3′-UTR aid translation of protein.
“5′-UTR regulatory elements and the length of the 3′-UTR aid translation of protein.”
Quote in the paperSubstantial claimMay combine two claims.
Premisecitation5-methylcytidine (m5C) and pseudouridine (ψ) nucleotide modifications lower immunogenicity while increasing translation efficiency.
“5-methylcytidine (m5C) and pseudouridine (ψ) nucleotide modifications are commonly preferred in base-pair alterations as they lower immunogenicity while increasing the efficiency of translation (Weng 2020).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Weng 2020 source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Premisenone givenThe 5′ cap regulates pre-mRNA splicing and nuclear export.
“The 5′ cap regulates pre-mRNA splicing and nuclear export, works as a protective structure that shields RNA from exonuclease cleavage, and initiates mRNA translation.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationUnmodified mRNA showed no significant alterations and merely elicited a considerable immunological response.
“Unmodified mRNA, on the other hand, showed no significant alterations and merely elicited a considerable immunological response (Kormann et al. 2011).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Kormann et al. 2011 source
May combine two claims.
InterpretationreasoningThe translation and stability of mRNA can be improved.
“The translation and stability of mRNA can be improved and critical tasks have been undertaken to identify desirable mRNA elements.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationARCA-capped mRNA boosts and extends protein expression in cultured cells.
“ARCA-capped mRNA has been shown to boost and extend protein expression in cultured cells (Zohra et al. 2007).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Zohra et al. 2007 source
May combine two claims.
InterpretationreasoningTranslation efficiency, mRNA abundance, and protein folding may all be affected by codon optimization.
“Translation efficiency, mRNA abundance, and protein folding may all be affected by codon optimization.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningThese mRNA components can be modified or altered to increase the stability, translation efficiency, and immune-stimulatory feature of mRNA.
“These components can be modified or altered to increase the stability, translation efficiency, and immune-stimulatory feature of mRNA (Table 1).”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationmRNA does not interact with the genome and only the parts directly required for the encoded protein expression are present in the basic genetic construct.
“The mRNA also does not interact with the genome and only the parts directly required for the encoded protein expression are present in this basic genetic construct (Pardi et al. 2018).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Pardi et al. 2018 source
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
PremisecitationUTRs comprise regulatory regions related to mRNA stability, ribosome recognition, interaction with translational machinery components, and mRNA secondary structures.
“They comprise various regulatory regions related to mRNA stability, ribosome recognition, interaction with translational machinery components, and mRNA secondary structures (Tanguay and Gallie 1996).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Tanguay and Gallie 1996 source
Checked before — its earlier verdict is held back until a new check runs.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe start codon should include a Kozak sequence.
“The start codon should include Kozak sequence (Kozak 1986), and the stop codon's sequence can be modified (Liu 2005).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Kozak 1986 source
Classified as probably not a substantial claim.
PremisecitationThe 7-methylguanosine (m7G) moiety is found at the 5′ end of natural mRNA in the eukaryotic cytoplasm, followed by a triphosphate connection to the first nucleotide (m7GpppN).
“The 7-methylguanosine (m7G) moiety is found at the 5′ end of natural mRNA in the eukaryotic cytoplasm, followed by a triphosphate connection to the first nucleotide (m7GpppN) (Sahin et al. 2014).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Sahin et al. 2014 source
Not checked in the free run.
Probably not a substantial claim: may not pass S4 (based). May combine two claims.
Interpretationnone givenOptimizing mRNA structural features, particularly the 5′ cap, 5′ and 3′UTRs, the coding region, and the poly(A) tail, increases the mRNA's control of immune responses, resulting in higher translational efficiency.
“Optimizing the mRNA structural features particularly the 5′ cap, 5′ and 3′UTRs, the coding region, and the poly(A) tail increases the mRNA’s control of immune responses resulting in higher translational efficiency.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenThe efficacy of both the mRNA vaccines is more than 90% (~95% to be precise).
“The efficacy of both the mRNA vaccines is more than 90% (~ 95% to be precise).”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationThe COVID-19 vaccine candidates demonstrate the structurally modified mRNA approach allows for higher tolerated doses and may be more suitable for producing a fast antibody response.
“The COVID-19 vaccine candidates demonstrate the structurally modified mRNA approach allows for higher tolerated doses and may be more suitable for producing a fast antibody response (Verbeke et al. 2021).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Verbeke et al. 2021 source
Not checked in the free run.
May combine two claims.
PremisecitationBNT162b2 uses 5′ UTR human β-globin RNA with optimized Kozak sequence, 3′ UTR AES and mtRNR1 3′ UTR motives, and 110 Poly(A) tail with nucleotide-linker (GCAUAUGACU).
“In addition, 5′ UTR: human -globin RNA with optimized Kozak sequence, 3′ UTR: AES and mtRNR1 3′ UTR Motives, and 110 Poly(A) tail with nucleotide-linker (GCAUAUGACU) are also used (Orlandini von Niessen et al. 2019).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Orlandini von Niessen et al. 2019 source
May combine two claims.
PremisecitationThe technique can be easily scaled requiring minimum platform changes during mRNA formulation and production.
“The technique can be easily scaled requiring minimum platform changes during mRNA formulation and production (Pardi et al. 2018).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Pardi et al. 2018 source
Not checked in the free run.
Probably not a substantial claim: may not pass S4 (based).
Interpretationnone givenModifying or improving mRNA structural features can boost the mRNA's potential to control innate immune responses, resulting in increased translation capacity and bioavailability.
“Modifying or improving the structural features can boost the mRNA’s potential to control innate immune responses, resulting in increased translation capacity and bioavailability.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenLong term effects of the mRNA vaccine are unknown.
“Despite the advantages of mRNA vaccines there are still many risks involved such as long term effects of the mRNA vaccine are unknown.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Interpretationnone givenmRNA vaccines provide flexibility in development because any protein can be made from mRNA without changing the production or application procedure.
“mRNA vaccines provide flexibility in development as any protein can be made from mRNA without changing the production or application procedure.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenSpike proteins with K986P, V987P substitutions are common in both vaccines.
“Spike proteins with K986P, V987P substitutions are common in both vaccines.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable), S4 (based).
InterpretationreasoningOptimizing the structure of mRNA can dramatically improve the final result.
“The final result can be dramatically improved by optimizing the structure of mRNA.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenEnzymatic polyadenylation has the disadvantage of producing a variety of RNA species with variable poly(A) tail lengths in each RNA preparation.
“Enzymatic polyadenylation has the disadvantage of having a variety of RNA species with variable poly(A) tail lengths in each RNA preparation.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.
PremisereasoningmRNA is a transient molecule that carries a short translation sequence and has no interaction with the host genome.
“Furthermore, mRNA is a transient molecule carries a short translation sequence it has no interaction with the host genome.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationProtein-based vaccinations are usually made from bacteria, whereas mRNA vaccines can be produced by the host translation machinery, resulting in an antigen that closely resembles the structure of the protein released from the viral genome.
“Protein-based vaccinations are usually made from bacteria, however mRNA vaccines can be produced by the host translation machinery, resulting in an antigen that closely resembles the structure of the protein released from the viral genome (Park et al. 2021).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Park et al. 2021 source
Checked before — its earlier verdict is held back until a new check runs.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenVaccine development often requires years of research and testing to ensure efficacy and safety.
“Vaccine development often requires years of research and testing to ensure efficacy and safety.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationPoly(A) tails of approximately 100 nt are ideal for synthesizing mRNA therapies because tail size affects mRNA decay by modulating 3′ exonucleolytic degradation.
“Poly(A) tails of approximately 100 nt are ideal for synthesizing mRNA therapies because tail size affects mRNA decay by modulating 3′ exonucleolytic degradation (Schlake et al. 2012).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Schlake et al. 2012 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationHPLC, anion exchange and affinity chromatography are used in the purification process to remove truncated transcripts.
“HPLC, anion exchange and affinity chromatography, are used in the purification process to remove truncated transcripts (Weissman et al. 2013).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Weissman et al. 2013 source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationIVT is a low-cost method of mRNA synthesis.
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Sahin et al. 2014 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenThe COVID-19 pandemic has increased the interest in mRNA vaccinations.
“The COVID-19 pandemic has increased the interest in mRNA vaccinations.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisenone givenmRNA vaccines work on the principle of delivering a transcript that encodes a target antigen or immunogen.
“mRNA vaccines work on the principle of delivering a transcript that encodes a target antigen or immunogen.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningIVT of RNA from a DNA template produces RNA with a predetermined poly(A) tail length, which is preferable, particularly for clinical purposes.
“Contrarily, in vitro transcription (IVT) of RNA from a DNA template produces RNA with a predetermined poly(A) tail length, which is preferable, particularly for clinical purposes.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningmRNA vaccines have greater biosafety than DNA vaccines because their antigens are translated in the cytoplasm and mRNA is less likely to integrate into the genome.
“Because antigen translation occurs in the cytoplasm rather than the nucleus; therefore mRNA vaccines have a greater biosafety than DNA vaccines as their antigens are translated into the cytoplasm rather than the nucleus, making it more difficult for the mRNA to integrate into the genome.”
Quote in the paperNot a substantial claimMay combine two claims.
Premisenone givenAdding poly(A) tails lowers mRNA immunogenicity by lowering U content and shielding mRNA in the sequence.
“Adding poly(A) tails lowers mRNA immunogenicity by lowering U content and shielding mRNA in the sequence.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
InterpretationreasoningBecause of the ease and speed with which mRNA vaccines may be produced, they are often favored over alternative platforms.
“Because of the ease and speed with which mRNA vaccines may be produced, they are often favored over alternative platforms.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenThe two mRNA vaccines took less than a year to develop and deploy from start to finish.
“In contrast, the two mRNA vaccines took less than a year to develop and deploy from start to finish.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
InterpretationreasoningThe rapid creation, manufacture, and excellent effectiveness in preventing SARS-CoV-2 infection show that mRNA-based therapies are ready for application in the future.
“Their rapid creation, manufacture, and excellent effectiveness in preventing SARS-CoV-2 infection, show that mRNA-based therapies are ready for application in the future.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Premisenone givenAfter transfection, mRNA vaccine expresses the protein target (antigen) via translation from mRNA.
“After transfection, mRNA vaccine expresses the protein target (antigen) via translation from mRNA.”
Quote in the paperSubstantial claim
The paper relies on this without support.
mRNA is susceptible to degradation and stabilizing it may lead to high expression.
“The mRNA is susceptible to degradation and stabilizing it may lead to high expression.”
The paper relies on this without support.
The intensity and specificity of the immune responses are influenced by changes in mRNA structure, translational efficiency, and protein-folding machinery.
“The intensity and specificity of the immune responses are expected to be influenced by these changes.”
The paper relies on this without support.
mRNA is unstable and must be stored at high temperature, making packaging and distribution of vaccine difficult.
“mRNA is also unstable and must be stored at high temperature making packaging and distribution of vaccine difficult.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
UTRs can influence mRNA translation efficiency and resistance to degradation by interacting with RNA-binding proteins and microRNAs.
“It is known that UTRs are associated with processes of mRNA translation, and by interacting with RNA-binding proteins (RBPs) and microRNAs, UTRs can influence mRNA’s translation efficiency and resistance to degradation [3,4,5,6,7].”
From Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis (2024) · cites this paper as [6]
The “5ʹ- and 3ʹ-UTRs” section says that UTR interactions with RNA-binding proteins can influence mRNA degradation and translation efficiency. It does not mention microRNAs as part of that mechanism, so that portion of the attributed claim is unsupported by our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredModifying the structural elements of mRNA including the 5′ cap, 5′-and 3′-untranslated regions, the coding region, and polyadenylation tail help improved the intracellular stability of mRNA.
“For mRNA vaccine, modifying the structural elements of mRNA including the 5′ cap, 5′-and 3′-untranslated regions, the coding region, and polyadenylation tail help improved the intracellular stability of mRNA (55).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Conflicting mRNA vaccine storage temperatures
MinorThe paper says mRNA vaccines must be stored at extremely low temperatures, then says they must be stored at high temperature.
“mRNA vaccines must be stored and carried at extremely low temperatures”
“mRNA is also unstable and must be stored at high temperature making packaging and distribution of vaccine difficult.”
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741 · see citing works
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works
A "Silent" Polymorphism in the <i>MDR</i> 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416 · see citing works
AU-rich elements: characterization and importance in mRNA degradation
Chen, C.-Y. A., & Shyu, A.-B. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89102-1 · Cited by 1,948 · see citing works
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · see citing works
Codon Optimality Is a Major Determinant of mRNA Stability
Presnyak, V., Alhusaini, N., Chen, Y.-H., Martin, S., Morris, N., Kline, N., Olson, S., Weinberg, D., Baker, K. E., Graveley, B. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.029 · Cited by 1,078 · see citing works
Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them
Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949 · see citing works
The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency.
Gallie, D. R. (1991) · Genes & Development · doi:10.1101/gad.5.11.2108 · Cited by 868 · see citing works
Codon optimality, bias and usage in translation and mRNA decay
Hanson, G., & Coller, J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.91 · Cited by 825 · see citing works
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733 · see citing works
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · see citing works
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624 · see citing works
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622 · see citing works
mRNA structure regulates protein expression through changes in functional half-life
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555 · see citing works
A nuclear cap binding protein complex involved in pre-mRNA splicing
Izaurralde, E., Lewis, J., McGuigan, C., Jankowska, M., Darzynkiewicz, E., & Mattaj, I. W. (1994) · Cell · doi:10.1016/0092-8674(94)90530-4 · Cited by 517 · see citing works
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517 · see citing works
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504 · see citing works
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · see citing works
High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells
Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040180 · Cited by 476 · see citing works
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422 · see citing works
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417 · see citing works
Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365 · see citing works
Devarkar, S. C., Wang, C., Miller, M. T., Ramanathan, A., Jiang, F., Khan, A. G., Patel, S. S., & Marcotrigiano, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515152113 · Cited by 357 · see citing works
A Role for Codon Order in Translation Dynamics
Cannarozzi, G., Schraudolph, N. N., Faty, M., von Rohr, P., Friberg, M. T., Roth, A. C., Gonnet, P., Gonnet, G., & Barral, Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.036 · Cited by 354 · see citing works
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · see citing works
(2001) · PubMed Central · Cited by 342 · see citing works
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342 · see citing works
(1995) · PubMed · Cited by 330 · see citing works
mRNA vaccines for COVID-19: what, why and how
Park, J. W., Lagniton, P. N. P., Liu, Y., & Xu, R.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59233 · Cited by 321 · see citing works
The influence of codon context on genetic code translation
Bossi, L., & Roth, J. R. (1980) · Nature · doi:10.1038/286123a0 · Cited by 284 · see citing works
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282 · see citing works
Poly(A) Tail Shortening by a Mammalian Poly(A)-specific 3′-Exoribonuclease
Körner, C. G., & Wahle, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10448 · Cited by 230 · see citing works
Translational Efficiency Is Regulated by the Length of the 3′ Untranslated Region
Tanguay, R. L., & Gallie, D. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.1.146 · Cited by 204 · see citing works
Regulation of Poly(A) Tail and Translation during the Somatic Cell Cycle
Park, J.-E., Yi, H., Kim, Y., Chang, H., & Kim, V. N. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.007 · Cited by 202 · see citing works
Self-citationTheoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Sperberg, R. A. P., Huang, P.-S., Participants, E., & Das, R. (2020) · doi:10.1101/2020.08.22.262931 · Cited by 199 · see citing works
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Parra Sperberg, R. A., Huang, P.-S., Participants, E., & Das, R. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab764 · Cited by 197 · see citing works
HPLC purification of in vitro transcribed long RNA
Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180 · see citing works
Determinants and implications of mRNA poly(A) tail size – Does this protein make my tail look big?
Jalkanen, A. L., Coleman, S. J., & Wilusz, J. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.05.018 · Cited by 154 · see citing works
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126 · see citing works
Vaccine technologies: view to the future
Rabinovich, N. R., McInnes, P., Klein, D. L., & Hall, B. (1994) · Science · doi:10.1126/science.7521064 · Cited by 98 · see citing works
pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences
Grier, A. E., Burleigh, S., Sahni, J., Clough, C. A., Cardot, V., Choe, D. C., Krutein, M. C., Rawlings, D. J., Jensen, M. C., Scharenberg, A. M., et al. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.21 · Cited by 95 · see citing works
Differential Inhibition of mRNA Degradation Pathways by Novel Cap Analogs
Grudzien, E., Kalek, M., Jemielity, J., Darzynkiewicz, E., & Rhoads, R. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509121200 · Cited by 90 · see citing works
Karikó, K., Kuo, A., & Barnathan, E. S. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300930 · Cited by 89 · see citing works
Zohra, F. T., Chowdhury, E. H., Tada, S., Hoshiba, T., & Akaike, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.059 · Cited by 71 · see citing works
Zhong, C., Wei, P., & Zhang, Y. P. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26238 · Cited by 41 · see citing works
Comparative analysis of base biases around the stop codons in six eukaryotes
Liu, Q. (2005) · Biosystems · doi:10.1016/j.biosystems.2005.05.005 · Cited by 29 · see citing works
Globin gene transcripts can utilize histone gene 3′ end processing signals
Whitelaw, E., Coates, A., & Proudfoot, N. J. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.17.7059 · Cited by 17 · see citing works
Homma, K., Noguchi, T., & Fukuchi, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw899 · Cited by 15 · see citing works
In vitro Transcription and Capping of Gaussia Luciferase mRNA Followed by HeLa Cell Transfection
Jani, B., & Fuchs, R. T. (2012) · Journal of Visualized Experiments · doi:10.3791/3702 · Cited by 13 · see citing works
Urbina, F., Morales, S., & Maldonado, E. (2020) · Polymers · doi:10.3390/polym12081633 · Cited by 11 · see citing works
Arbuthnot, P. B., Ely, A., & Bloom, K. M. (2019) · BioTechniques · doi:10.2144/btn-2018-0120 · Cited by 9 · see citing works
In vitro Transcription and Capping of Gaussia Luciferase mRNA Followed by HeLa Cell Transfection
Jani, B., & Fuchs, R. (2012) · Journal of Visualized Experiments · doi:10.3791/3702-v
Flagged first, then by citations
Cited by
Sorted by citations
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 864 · see citing works
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina‐Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 296 · see citing works
mRNA vaccines for cancer immunotherapy
Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029069 · Cited by 180 · see citing works
Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines
Kim, B., Hosn, R. R., Remba, T. K., Yun, D. S., Li, N., Abraham, W. D., Melo, M. B., Cortés, M., Li, B., Zhang, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.022 · Cited by 154 · see citing works
mRNA vaccine in cancer therapy: Current advance and future outlook
Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 152 · see citing works
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 146 · see citing works
mRNA in the Context of Protein Replacement Therapy
Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 143 · see citing works
Zhang, H., Vandesompele, J., Braeckmans, K., Smedt, S. C. D., & Remaut, K. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00194f · Cited by 140 · see citing works
Direct in vivo CAR T cell engineering
Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 134 · see citing works
Amplifying gene expression with RNA-targeted therapeutics
Khorkova, O., Stahl, J., Joji, A., Volmar, C., & Wahlestedt, C. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00704-7 · Cited by 132 · see citing works
Quality by Design for enabling RNA platform production processes
Daniel, S., Kis, Z., Kontoravdi, C., & Shah, N. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.03.012 · Cited by 128 · see citing works
Recent Advances in Cardiovascular Disease Biosensors and Monitoring Technologies
Tang, L., Yang, J., Wang, Y., & Deng, R. (2023) · ACS Sensors · doi:10.1021/acssensors.2c02311 · Cited by 120 · see citing works
Xu, X., Wang, X., Liao, Y., Luo, L., Xia, T., & Nel, A. E. (2023) · ACS Nano · doi:10.1021/acsnano.2c12420 · Cited by 114 · see citing works
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 113 · see citing works
Kafetzis, K. N., Papalamprou, N., McNulty, E., Thong, K. X., Sato, Y., Mironov, A., Purohit, A., Welsby, P. J., Harashima, H., Yu‐Wai‐Man, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203022 · Cited by 96 · see citing works
mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases
Le, T., Sun, C., Chang, J., Zhang, G., & Yin, X. (2022) · Viruses · doi:10.3390/v14020401 · Cited by 93 · see citing works
A comprehensive comparison of DNA and RNA vaccines
Wang, C., & Yuan, F. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115340 · Cited by 87 · see citing works
Understanding nucleic acid sensing and its therapeutic applications
Kong, L.-Z., Kim, S., Wang, C., Lee, S. Y., Oh, S., Lee, S., Jo, S., & Kim, T. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01118-6 · Cited by 84 · see citing works
Self-citationKis, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020430 · Cited by 83 · see citing works
Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79 · see citing works
“For mRNA vaccine, modifying the structural elements of mRNA including the 5′ cap, 5′-and 3′-untranslated regions, the coding region, and polyadenylation tail help improved the intracellular stability of mRNA (55).”
BackgroundMuthamil, S., Kim, H., Jang, H., Lyu, J., Shin, U. C., Go, Y., Park, S., Lee, H. G., & Park, J. H. (2024) · Advanced Biology · doi:10.1002/adbi.202400079 · Cited by 79 · see citing works
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 72 · see citing works
Tbeishat, H. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-08506-4 · Cited by 69 · see citing works
Breaking the mold with RNA—a “RNAissance” of life science
Jones, C. H., Androsavich, J. R., So, N., Jenkins, M. P., MacCormack, D., Prigodich, A. E., Welch, V., True, J. M., & Dolsten, M. (2024) · npj Genomic Medicine · doi:10.1038/s41525-023-00387-4 · Cited by 65 · see citing works
Advances and prospects of RNA delivery nanoplatforms for cancer therapy
Attia, M. S., Kijanka, G. S., Nguyen, N., Zhang, J., & An, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.009 · Cited by 64 · see citing works
Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
Youssef, M., Hitti, C., Fulber, J. P. C., & Kamen, A. (2023) · Biomolecules · doi:10.3390/biom13101497 · Cited by 62 · see citing works
mRNA vaccines: a new era in vaccine development
Chandra, S., Wilson, J. C., Good, D. M., & Wei, M. Q. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043987 · Cited by 58 · see citing works
A Review on the Stability Challenges of Advanced Biologic Therapeutics
Sarvepalli, S., Pasika, S. R., Verma, V., Thumma, A., Bolla, S., Nukala, P. K., Butreddy, A., & Bolla, P. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050550 · Cited by 58 · see citing works
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 57 · see citing works
Liu, X., Li, Z., Li, X., Wu, W., Jiang, H., Zheng, Y., Zhou, J., Ye, X., Lu, J., Wang, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53242-0 · Cited by 57 · see citing works
Potential health risks of mRNA-based vaccine therapy: A hypothesis
Acevedo‐Whitehouse, K. A., & Bruno, R. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111015 · Cited by 54 · see citing works
Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus
Ma, S., Zhu, F., Xu, Y., Wen, H., Rao, M., Zhang, P., Peng, W., Cui, Y., Yang, H., Tan, C., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2293300 · Cited by 53 · see citing works
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 51 · see citing works
Arte, K. S., Chen, M., Patil, C. D., Huang, Y., Qu, L. L., & Zhou, Q. T. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.12.013 · Cited by 51 · see citing works
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 49 · see citing works
Webb, A. L. J., Welbourne, E. N., Evans, C. A., & Dickman, M. J. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.465724 · Cited by 49 · see citing works
Characterization of mRNA therapeutics
Guimaraes, G. J., Kim, J., & Bartlett, M. G. (2023) · Mass Spectrometry Reviews · doi:10.1002/mas.21856 · Cited by 48 · see citing works
Research progress on the quality control of mRNA vaccines
Hu, C., Bai, Y., Liu, J., Wang, Y., He, Q., Zhang, X., Cheng, F., Xu, M., Mao, Q., & Liang, Z. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2354251 · Cited by 45 · see citing works
Advances in nucleic acid-based cancer vaccines
Liao, H., & Liu, S. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01102-w · Cited by 45 · see citing works
Rohde, C. M., Lindemann, C., Giovanelli, M. A., Sellers, R. S., Diekmann, J., Choudhary, S., Ramaiah, L., Vogel, A. B., Chervona, Y., Muik, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020417 · Cited by 44 · see citing works
Development of Thermally Stable mRNA-LNP Delivery Systems: Current Progress and Future Prospects
Kafle, U., Truong, H. Q., Cao, T. G. N., & Meng, F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00826 · Cited by 44 · see citing works
Advancements in monkeypox vaccines development: a critical review of emerging technologies
Garcia-Atutxa, I., Mondragón‐Terán, P., Saquero, A. H., & Villanueva‐Flores, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456060 · Cited by 43 · see citing works
Recent advances in electrochemical nanobiosensors for cardiac biomarkers
Negahdary, M., Sharma, A., Anthopoulos, T. D., & Angnes, L. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117104 · Cited by 42 · see citing works
Miller, M. G., Alvizo, O., Baskerville, S., Chintala, A., Chng, C., Dassie, J. P., Dorigatti, J. D., Huisman, G. W., Jenne, S., Kadam, S., et al. (2024) · Faraday Discussions · doi:10.1039/d4fd00023d · Cited by 40 · see citing works
Thau, H., Neuber, S., Emmert, M. Y., & Nazari‐Shafti, T. Z. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00353-w · Cited by 39 · see citing works
Ramadan, E., Ismeal, A. A. A., & Naguib, Y. W. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14111092 · Cited by 38 · see citing works
Okuyama, R. (2023) · Vaccines · doi:10.3390/vaccines11121737 · Cited by 37 · see citing works
The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV)
Movahed, F., Darzi, S., Mahdavi, P., Mahdi, M. S., Allela, O. Q. B., Sameer, H. N., Adil, M., Zarkhah, H., Yasamineh, S., & Gholizadeh, O. (2024) · Virology Journal · doi:10.1186/s12985-024-02397-9 · Cited by 36 · see citing works
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 36 · see citing works
mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation
Jacques Demongeot, A., & Fougère, C. (2022) · Vaccines · doi:10.3390/vaccines11010040 · Cited by 35 · see citing works
mRNA Synthesis and Encapsulation in Ionizable Lipid Nanoparticles
McKenzie, R. E., Minnell, J. J., Ganley, M., Painter, G. F., & Draper, S. L. (2023) · Current Protocols · doi:10.1002/cpz1.898 · Cited by 35 · see citing works
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 34 · see citing works
The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections
You, H., Jones, M. K., Gordon, C. A., Arganda, A. E., Cai, P., Al-Wassiti, H., Pouton, C. W., & McManus, D. P. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00241-21 · Cited by 34 · see citing works
Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis
Reshetnikov, V., Terenin, I., Shepelkova, G., Yeremeev, V., Kolmykov, S., Nagornykh, M., Kolosova, E., Sokolova, T., Zaborova, O., Kukushkin, I., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020888 · Cited by 33 · see citing works
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 33 · see citing works
Novel Vectors and Administrations for mRNA Delivery
Bai, C., Wang, C., & Lu, Y. (2023) · Small · doi:10.1002/smll.202303713 · Cited by 32 · see citing works
Xu, Y., Zhu, F., Zhou, Z., Ma, S., Zhang, P., Tan, C., Luo, Y., Qin, R., Chen, J., & Pan, P. (2024) · BMC Genomics · doi:10.1186/s12864-024-10691-7 · Cited by 30 · see citing works
Mukhtar, M., Wajeeha, A. W., Zaidi, N. U. S. S., & Bibi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213911 · Cited by 30 · see citing works
Developing mRNA Nanomedicines with Advanced Targeting Functions
Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 29 · see citing works
Have mRNA vaccines sentenced DNA vaccines to death?
Cagigi, A., & Douradinha, B. G. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2282065 · Cited by 29 · see citing works
Chung, S., Lee, C. M., & Zhang, M. (2022) · Nanoscale Horizons · doi:10.1039/d2nh00289b · Cited by 27 · see citing works
Kuzmin, I. V., Soto-Acosta, R., Pruitt, L., Wasdin, P. T., Kedarinath, K., Hernandez, K. R., Gonzales, K. A., Hill, K., Weidner, N. G., Mire, C. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50774-3 · Cited by 26 · see citing works
Lu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 26 · see citing works
mRNA vaccines: immunogenicity and quality characteristics
Quan, Y., Yang, H., Li, W., & Li, L. X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03800-5 · Cited by 26 · see citing works
Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
Liu, C., Rcheulishvili, N., Shen, Z., Papukashvili, D., Xie, F., Wang, Z., Wang, X., He, Y., & Wang, P. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051101 · Cited by 26 · see citing works
Role of N6‐methyladenosine RNA modification in cancer
Qu, Y., Gao, N., Zhang, S., Gao, L., He, B., Wang, C., Gong, C., Shi, Q., Li, Z., Yang, S., et al. (2024) · MedComm · doi:10.1002/mco2.715 · Cited by 25 · see citing works
Moon, J. H., Phoo, M. T., Kim, Y., Ahn, J., Kim, A., Nam, J., Lee, S., Moon, J. J., & Son, S. (2025) · Advanced Science · doi:10.1002/advs.202509022 · Cited by 25 · see citing works
Self-citationDendrimer-based nanocomposites for the production of RNA delivery systems
Chyi, L. C., Chia, L. Y., & Kumar, P. V. (2023) · OpenNano · doi:10.1016/j.onano.2023.100173 · Cited by 25 · see citing works
Olowe, G. T., Oyovwi, M. O., Nwangwa, K. E., Ejiro, O. P., & Oghenetega, O. B. (2024) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00025s · Cited by 23 · see citing works
Wang, P., Ju, C., Zhao, M., Jiang, B., & He, C. (2025) · Nature Chemistry · doi:10.1038/s41557-025-01801-3 · Cited by 23 · see citing works
Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses
Kutikuppala, L. V. S., Kourampi, I., Kanagala, R. S. D., Bhattacharjee, P., & Boppana, S. H. (2024) · Medical Sciences · doi:10.3390/medsci12020028 · Cited by 23 · see citing works
Yaseen, A. R., Suleman, M., Qadri, A. S., Ali, A., Arshad, I., & Khan, D. M. (2023) · In Silico Pharmacology · doi:10.1007/s40203-023-00156-2 · Cited by 22 · see citing works
The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
Jamous, Y. F., & Alhomoud, D. A. (2023) · Cureus · doi:10.7759/cureus.45602 · Cited by 22 · see citing works
Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progress
Li, S., Zheng, L., Zhong, J., & Gao, X. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253009 · Cited by 21 · see citing works
Not so cold! Improving the thermostability of mRNA vaccines
Haensler, J., Even, L., Wils, P., Bensaid, F., Dias, A., Deng, H., Karve, S., & DeRosa, F. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2596674 · Cited by 21 · see citing works
Mahony, T. J., Briody, T. E., & Ommeh, S. C. (2024) · Vaccines · doi:10.3390/vaccines12020152 · Cited by 21 · see citing works
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sheikhlary, S., Lopez, D. H., Moghimi, S., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14040503 · Cited by 21 · see citing works
Genetic adjuvants: A paradigm shift in vaccine development and immune modulation
Spunde, K., Korotkaja, K., Sominskaya, I., & Zajakina, A. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102536 · Cited by 20 · see citing works
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 20 · see citing works
Fernandes, R. S., Burle-Caldas, G. D. A., Sérgio, S. A. R., Bráz, A. F., Leite, N. P. D. S., Pereira, M. C. A., Silva, J. D. O., Hojo-Souza, N. S., de Oliveira, B., Fernandes, A. P., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03201-8 · Cited by 19 · see citing works
Karan, S., Duran-Meza, A. L., Chapman, A., Tanimoto, C. R., Chan, S. K., Knobler, C. M., Gelbart, W. M., & Steinmetz, N. F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01105 · Cited by 19 · see citing works
Advances in non-viral mRNA delivery to the spleen
Narasipura, E. A., & Fenton, O. S. (2024) · Biomaterials Science · doi:10.1039/d4bm00038b · Cited by 19 · see citing works
COVID-19 Variants and Vaccine Development
Zhao, Z., Bashiri, S., Ziora, Z. M., Tóth, I., & Skwarczyński, M. (2024) · Viruses · doi:10.3390/v16050757 · Cited by 19 · see citing works
Ma, S., Zhu, F., Zhang, P., Xu, Y., Zhou, Z., Yang, H., Tan, C., Chen, J., & Pan, P. (2025) · Scientific Reports · doi:10.1038/s41598-024-84823-0 · Cited by 19 · see citing works
Mechanistic modeling of lipid nanoparticle formation for the delivery of nucleic acid therapeutics
Inguva, P., Mukherjee, S., Walker, P. J., Tenberg, V., Devos, C., Shin, S., Wu, Y., Santra, S., Wang, J., Singh, S., et al. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108643 · Cited by 18 · see citing works
Self-citationModified Nucleotides for Chemical and Enzymatic Synthesis of Therapeutic RNA
Graczyk, A., Radzikowska‐Cieciura, E., Kaczmarek, R., Pawłowska, R., & Chworoś, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221014111403 · Cited by 18 · see citing works
Guo, X., Liu, D., Huang, Y., Deng, Y., Wang, Y., Mao, J., Zhou, Y., Xiong, Y., & Gao, X. (2023) · Virology Journal · doi:10.1186/s12985-023-02023-0 · Cited by 17 · see citing works
Advancement in the development of mRNA ‐based vaccines for respiratory viruses
Troncoso‐Bravo, T., Ramírez, M. A., Loaiza, R. A., Román-Cárdenas, C., Papazisis, G., Garrido, D. A., González, P. A., Bueno, S. M., & Kalergis, A. M. (2024) · Immunology · doi:10.1111/imm.13844 · Cited by 17 · see citing works
mRNA-LM: full-length integrated SLM for mRNA analysis
Li, S., Noroozizadeh, S., Moayedpour, S., Kogler-Anele, L., Xue, Z., Zheng, D., Montoya, F. U., Agarwal, V., Bar‐Joseph, Z., & Jäger, S. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf044 · Cited by 17 · see citing works
mRNA vaccine development and applications: A special focus on tumors (Review)
Chen, B., Yang, Y., Wang, X., Yang, W., Lu, Y., Wang, D., Zhuo, E., Tang, Y., Su, J., Tang, G., et al. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5669 · Cited by 16 · see citing works
RNA methylations in depression, from pathological mechanism to therapeutic potential
Li, C., Xu, P., Huang, Y., Wang, Y., Wu, Y., Li, H., Peng, Y., Wang, X., Li, G., He, J., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115750 · Cited by 16 · see citing works
The global patent landscape of mRNA for diagnosis and therapy
Lyu, M., Chen, J., Peng, Y., Han, F., Gong, L., Guo, J., Tian, L., & Gao, Y. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01925-2 · Cited by 16 · see citing works
Tran, J. P., Gao, J., Lansdell, C., Lorbetskie, B., Johnston, M., Wang, L., Li, X., & Lu, H. (2025) · Electrophoresis · doi:10.1002/elps.8123 · Cited by 15 · see citing works
Maziec, K., Baliga-Gil, A., & Kierzek, E. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102572 · Cited by 15 · see citing works
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15 · see citing works
Stiving, A. Q., Roose, B. W., Tubbs, C. M., Haverick, M. A., Gruber, A., Rustandi, R. R., Kuiper, J. L., Schombs, M. W., Schuessler, H. A., & Li, X. (2025) · npj Vaccines · doi:10.1038/s41541-025-01082-4 · Cited by 15 · see citing works
Making the Next Generation of Therapeutics: mRNA Meets Synthetic Biology
Hınçer, A., Ahan, R. E., Aras, E., & Şeker, U. Ö. Ş. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00253 · Cited by 15 · see citing works
Process and analytical strategies for the safe production of mRNA vaccines and therapeutics
Nowak, C. J. A., Liu, S., Falconer, R. J., & Gerstweiler, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11455-0 · Cited by 14 · see citing works
Intradermal Delivery of Naked mRNA Vaccines via Iontophoresis
Hasan, M., Khatun, A., & Kogure, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122678 · Cited by 14 · see citing works
Innate Sensing of Viral Nucleic Acids and Their Use in Antiviral Vaccine Development
Enya, T., & Ross, S. R. (2025) · Vaccines · doi:10.3390/vaccines13020193 · Cited by 14 · see citing works
- Authors
- Kim, S. C., Sekhon, S. S., Shin, W.-R., Ahn, G., Cho, B.-K., Ahn, J.-Y., & Kim, Y.-H.
- Affiliations
- Korea Advanced Institute of Science and Technology (KR)
- Chungbuk National University (KR)
- Corresponding author
- Kim, Yang-Hoon
- Venue
- Molecular & Cellular Toxicology
- Published
- 2021-09-20
- Volume
- 18
- Issue
- 1
- Pages
- 1-8
- ISSN
- 1738-642X (ISSN-L)
- 2092-8467
- PMC
- PMC8450916
- OpenAlex
- W3201215980
- Cited by
- 255
- References
- 57
- Citations by year
- 2026: 38 · 2025: 79 · 2024: 68 · 2023: 46 · 2022: 22 · 2021: 1 · 2020: 1
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Molecular & Cellular Toxicology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- national research foundation of korea (2020R1A6A1A06046235, 2019R1A2C1010860)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- mRNA vaccines, mRNA stability, translation efficiency, 5' cap, 5' untranslated region, 3' untranslated region, polyadenylation, vaccine optimization, viral infection therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-11-05.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-11-05.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review